AbbVie Inc. (ABBV)
ABBV trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1551152/000155115226000008/0001551152-26-000008-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | ABBV on NYSE |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2012 |
| SEC CIK | 0001551152 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $61.2B |
| Net income | $4.2B |
| Operating income | $15.1B |
| Net margin | 6.9% |
| Operating margin | 24.6% |
| Revenue growth | +8.6% |
| Cash | $5.2B |
| Total assets | $134.0B |
| P/E (computed) | 123.2× |
| P/S (computed) | 8.5× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-03 |
| Cash and burn | $10.8B cash; operating cash flow $5.0B a quarter. | Report 2026-09-30 |
| Shares outstanding | 1,767,616,306 (2026-10-26); 1,767,384,632 a year earlier; 1,765,537,421 three years earlier. | Cover page 2026-10-26 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 4 424B5 takedowns | Latest 2026-08-06 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, Chicago, Illinois, United States | PCAOB Form AP 2026-03-16 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $18.9M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $17.4B | $4.2B | $7.6B | $10.8B | $80.9B | $66.0B | 10-Q 2026-11-03 |
| Q2 2026 2026-06-30 | $17.0B | $3.6B | $3.4B | $6.6B | $70.8B | $64.4B | 10-Q 2026-08-03 |
| Q1 2026 2026-03-31 | $15.0B | $695.0M | $3.8B | $9.4B | $72.9B | $62.8B | 10-Q 2026-05-08 |
| Q4 2025 2025-12-31 | $16.6B | $1.8B | $5.2B | $5.2B | $67.0B | $61.2B | 10-K 2026-02-20 |
| Q3 2025 2025-09-30 | $15.8B | $186.0M | $7.0B | $5.6B | $68.7B | $59.6B | 10-Q 2026-11-03 |
| Q2 2025 2025-06-30 | $15.4B | $938.0M | $5.2B | $6.5B | $70.5B | $58.3B | 10-Q 2026-08-03 |
| Q1 2025 2025-03-31 | $13.3B | $1.3B | $1.6B | $5.2B | $69.9B | $57.4B | 10-Q 2026-05-08 |
| Q4 2024 2024-12-31 | $15.1B | -$22.0M | $7.0B | $5.5B | $66.8B | $56.3B | 10-K 2025-02-14 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-08-06 |
| Latest annual report | 10-K | 2026-02-20 |
| Latest quarterly / interim | 10-Q | 2026-11-03 |
| Latest current report FORM 8-K | 8-K | 2026-11-02 |
| Latest proxy | DEFA14A | 2026-03-23 |
Source: SEC EDGAR submissions feed, 1,008 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +1.3% |
| 1 month | +7.5% |
| 3 months | +17.6% |
| Year to date | +29.1% |
| 1 year | +27.0% |
| From 52-week high | 0.0% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| JNJ | Johnson & Johnson | $282.55 | -1.12% | $680.2B |
| MRK | Merck & Company Inc. Common Stock (new) | $144.46 | -2.23% | $356.1B |
| NVS | Novartis AG | $160.20 | -0.19% | $305.7B |
| AZN | AstraZeneca PLC | $184.02 | -0.23% | $285.4B |
| LLY | Eli Lilly and Company | $1431.67 | -0.82% | $1.35T |
| ABT | Abbott Laboratories | $107.45 | -0.99% | $186.1B |
| NVO | Novo Nordisk A/S | $41.60 | -0.07% | $184.2B |
| PFE | Pfizer Inc. | $28.86 | -0.10% | $164.5B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier